Epstein-Barr virus Latent Membrane Protein 1 and 2 peptide-HLA class I complexes (EBV LMP1/LMP2 pMHC-I)

Epstein-Barr virus (EBV) Latent Membrane Protein 1 (LMP1) and 2 (LMP2) peptide-HLA class I complexes are critical immunological targets found on the surface of EBV-infected cells and associated malignancies (Young and Rickinson, Nat Rev Cancer, 2004). LMP1 and LMP2 are viral oncogenes expressed during EBV latency, playing key roles in cell transformation and survival. These proteins are processed intracellularly into short peptide epitopes and presented on the cell surface by Human Leukocyte Antigen (HLA) class I molecules for recognition by CD8+ cytotoxic T lymphocytes (Bollard and Heslop, Blood, 2016). Because these complexes are specifically derived from viral proteins and are absent on healthy non-infected cells, they serve as ideal targets for immunotherapy, including TCR-T cell therapies and EBV-specific CTLs like Tabelecleucel (Prockop et al., J Clin Invest, 2020). Therapeutic strategies focusing on these complexes aim to treat EBV-associated diseases such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorders (PTLD). However, challenges include the high polymorphism of HLA alleles and potential immune evasion through HLA downregulation by tumor cells (Thorley-Lawson, Nat Rev Immunol, 2001).

Other names

EBV LMP1/LMP2-specific pMHCLMP1/LMP2 peptide-MHC class I complexesEBV-associated antigen-MHC complexesLMP1/2-HLA-IEBV Latent Membrane Protein epitopes

Targeting of EBV-infected cells via T-cell receptor (TCR) recognition of viral peptides presented on HLA class I molecules, leading to directed cytotoxic T-lymphocyte (CTL) mediated lysis.